MedTrace Logo

Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

NCT02648464 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2020-06-09

No results posted yet for this study

Summary

This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent cardiovascular events among myocardial infarction patients. Half of the participants will receive hydroxychloroquine, whereas the other half will receive placebo during six months.

Conditions

Interventions

DRUG

Hydroxychloroquine

DRUG

Placebo

Sponsors & Collaborators

  • Finnish Foundation for Cardiovascular Research

    collaborator OTHER

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • Aarne Koskelo Foundation

    collaborator OTHER

  • Finnish Cultural Foundation

    collaborator OTHER

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Juha Sinisalo, Professor · Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648464 on ClinicalTrials.gov